Legend Capital and Zhongjinqichen, a healthcare, technology and consumer-focused private equity fund under China International Capital Co., Ltd have lead a RMB250 million (US$38 million) series B round in Bellen, a Chinese medical contract research organization (CRO).
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Read 2 Articles for Free with a Basic Account
Gain limited and restricted access to China Money Network.Register Basic Account
Subscribe for an annual subscription!
Enjoy comprehensive and exclusive data you can't find elsewhere!More Info
Already have an account or paid subscription?